Retro Biosciences is an anti-aging biotech that got lots of attention in April of 2022 after receiving $180 million from investors. It’s based in Redwood City, CA.

Retro Biosciences, which says it plans to launch trials for drugs targeting diseases like Alzheimer’s, recently trained a model with OpenAI to turn regular cells into stem cells.

Retro Biosciences is raising a $1bn round to fund the artificial intelligence-powered biotech’s mission to increase human lifespan by a decade, starting by getting its first drug into trials ...

OpenAI says it trained a new AI model called GPT-4b micro with Retro Biosciences, a longevity science startup trying to extend the human lifespan by 10 years, according to the MIT Technology Review.

Retro Biosciences Inc., a startup using artificial intelligence to discover new drugs, is reportedly raising $1 billion in funding to support its research.The Financial Times today cited sources a ...

But chances are that you’re not familiar with GPT-4b micro unless you’re involved in Retro Biosciences’ longevity work. The startup, which Sam Altman is an investor in, is studying ways to ...

Altman previously provided Retro Biosciences’ entire seed round of $180 million. Now, the startup is raising a $1 billion Series A that Altman is joining, The Financial Times reports.

OpenAI says it trained a new AI model called GPT-4b micro with Retro Biosciences, a longevity science startup trying to extend the human lifespan by 10 years, according to the MIT Technology Review.

OpenAI CEO Sam Altman is doubling down on Retro Biosciences, a biotech startup based in San Francisco that wants humans to live 10 years longer than what it calls a healthy human lifespan. Now ...

Retro Biosciences, a startup that aims to use AI to aid in drug development, is reportedly raising $1 billion to support its research, with investors including OpenAI, which has previously backed ...